In stock
Reta 20MG Pen
£135.00
Description
Retatrutide is an investigational, once-weekly injectable “triple hormone receptor agonist” (targeting GIP, GLP-1, and glucagon) developed by Eli Lilly for obesity and type 2 diabetes management. Known as a “triple-G” or “Godzilla” drug, Phase 3 trials suggest it may offer superior weight loss results (up to 28.7% over 68 weeks) compared to current therapies.
Features Product:
- GLP-1:Â Enhances satiety, reduces appetite, and promotes insulin secretion, directly supporting weight loss and blood glucose regulation.
- GIP:Â Facilitates improved insulin sensitivity and secretion, which are crucial for diabetes management.
- Glucagon: Increases energy expenditure by boosting metabolism, helping to mobilize fat stores effectively.
Care Instructions:
- Keep in the Fridge
- Maintain fridge temperature 5-7 Degrees
Important Safety and Compliance Information
Retatrutide supplied by our service is intended solely for in vitro laboratory research purposes. Regulatory authorities do not approve it for human or veterinary use. Researchers are responsible for ensuring adherence to all applicable local regulations and ethical standards. Retatrutide should not be used by anyone who is pregnant, breastfeeding, or has an existing health condition.
